PO4HB: A Promising Drug Target and Biomarker for the Treatment of Chronic Pain

Target Name: P4HB

NCBI ID: G5034

P4HB

PO4HB: A Promising Drug Target and Biomarker for the Treatment of Chronic Pain

Introduction

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that approximately 50% of the global population experiences chronic pain, with 10% of these individuals being in extreme pain. Chronic pain can be caused by various conditions, including neuropathic pain, rheumatoid arthritis, and cancer-related pain. These conditions can significantly impact an individual's quality of life, making it difficult to maintain an active lifestyle and engage in daily activities.

The identification of potential drug targets and biomarkers for the treatment of chronic pain is crucial for improving patient outcomes. One of the promising candidates in this field is PO4HB (poly(3-[2-(3-nitrophenyl]-1-propanethiol), also known as 2-nitrophenyl-3-propanethiol), a protein that has been shown to play a critical role in the development and progression of chronic pain.

PO4HB: Structure and Function

PO4HB is a 26-kDa protein that is expressed in various tissues, including brain, muscle, liver, and peripheral tissues. It is composed of two distinct domains: a N-terminal alpha-helical domain and a C-terminal T-loop domain . The N-terminal domain has a characteristic alpha-helical structure, which is responsible for the protein's stability and functions as a structural protein. The C-terminal domain is rich in conserved acidic and basic residues, which play a critical role in the protein's stability and localization to various cellular compartments.

In pain perception and neuroinflammation, PO4HB functions as an adapter protein. It has been shown to modulate the activity of various neurotransmitters, including nitric oxide (NO), which is involved in pain modulation. Additionally, PO4HB has been shown to interact with other proteins involved in pain signaling, such as TRPV1 and GPR117.

The efficacy of PO4HB as a drug target or biomarker for the treatment of chronic pain is its ability to modulate pain perception and neuroinflammation. Studies have shown that PO4HB has potent analgesic effects in animal models of chronic pain, including thermal pain, chemical pain, and neuroinvasive pain.

Molecular Mechanisms of PO4HB

The molecular mechanisms of PO4HB's analgesic and neuroinflammation-modulating properties are still being fully understood. However, several studies have provided insights into the protein's underlying mechanisms.

First, PO4HB has been shown to modulate the activity of pain-related neurotransmitters, such as NO and nitric oxide synthase (NOBS), which are involved in the production and regulation of pain signals. Specifically, PO4HB has been shown to enhance the production of NO and NOBS, which can lead to the relaxation of blood vessels and an improvement in pain perception.

Second, PO4HB has been shown to modulate the activity of pain-related intracellular signaling pathways, including the production and activation of pro-inflammatory cytokines, such as TNF-伪 and IL-1尾. These cytokines are involved in the recruitment of immune cells to the site of pain and contribute to the development of neuroinflammation.

Third, PO4HB has been shown to modulate the activity of pain-related ion channels, including Nav1.5, which is involved in pain perception and neurotransmission. The modulation of Nav1.5 channels by PO4HB has been shown to contribute to the protein's analgesia and neuroinflammation-modulating properties.

Drug Targeting and Biomarker Development

The potential drug targeting of PO4HB is high due to its unique mechanism of action and its potential to modulate multiple pain-related signaling pathways. Several compounds have been shown to interact with PO4HB and enhance its analgesic and neuroinflammation-modulating properties.

One of the most promising compounds is an oral Small Molecule Receptor (SMR) antagonist, SMR-301, which is currently in clinical trials for the treatment of chronic pain. SMR-301 has been shown to modulate Nav1.5 channels and to have potent Analgesic and neuroinflammation-modulating properties in animal models of chronic pain.

Another compound that has shown promise in the treatment of chronic pain is a peptide called P3T, which is derived from the N-terminal domain of PO4HB. P3T has been shown to have potent analgesic and neuroinflammation-modulating properties in animal models of chronic pain and may be a potential biomarker or drug target for the treatment of chronic pain.

Conclusion

PO4HB is a promising drug target and biomarker for the treatment of chronic pain due to its ability to modulate pain perception and neuroinflammation. The modulation of pain signals by PO4HB is mediated by its interaction with various neurotransmitters and signaling pathways, including NO, pro-inflammatory cytokines, and ion channels. Further research is needed to fully understand the molecular mechanisms of PO4HB's analgesic and neuroinflammation-modulating properties and to develop safe and effective drugs or biomarkers for the treatment of chronic pain.

Protein Name: Prolyl 4-hydroxylase Subunit Beta

Functions: This multifunctional protein catalyzes the formation, breakage and rearrangement of disulfide bonds. At the cell surface, seems to act as a reductase that cleaves disulfide bonds of proteins attached to the cell. May therefore cause structural modifications of exofacial proteins. Inside the cell, seems to form/rearrange disulfide bonds of nascent proteins. At high concentrations and following phosphorylation by FAM20C, functions as a chaperone that inhibits aggregation of misfolded proteins (PubMed:32149426). At low concentrations, facilitates aggregation (anti-chaperone activity). May be involved with other chaperones in the structural modification of the TG precursor in hormone biogenesis. Also acts as a structural subunit of various enzymes such as prolyl 4-hydroxylase and microsomal triacylglycerol transfer protein MTTP. Receptor for LGALS9; the interaction retains P4HB at the cell surface of Th2 T helper cells, increasing disulfide reductase activity at the plasma membrane, altering the plasma membrane redox state and enhancing cell migration (PubMed:21670307)

The "P4HB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about P4HB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets